D. E. Shaw & Co., Inc. Pacira Bio Sciences, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 2,253,365 shares of PCRX stock, worth $55.9 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,253,365
Previous 2,263,909
0.47%
Holding current value
$55.9 Million
Previous $56.3 Million
4.27%
% of portfolio
0.04%
Previous 0.06%
Shares
30 transactions
Others Institutions Holding PCRX
# of Institutions
256Shares Held
51.5MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$199 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$134 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$59.4 Million0.08% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$53.4 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.13MShares$52.9 Million0.08% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...